![Page 1: HIGH-FREQUENCY OSCILLATION: STATE OF THE EVIDENCE Niall D. Ferguson, MD, FRCPC, MSc Director, Critical Care Medicine University Health Network & Mount](https://reader038.vdocument.in/reader038/viewer/2022110116/551a845f550346e0158b4b45/html5/thumbnails/1.jpg)
HIGH-FREQUENCY OSCILLATION:STATE OF THE EVIDENCE
Niall D. Ferguson, MD, FRCPC, MScDirector, Critical Care Medicine
University Health Network & Mount Sinai Hospital
Associate Professor of Medicine & PhysiologyInterdepartmental Division of Critical Care Medicine
University of Toronto
![Page 2: HIGH-FREQUENCY OSCILLATION: STATE OF THE EVIDENCE Niall D. Ferguson, MD, FRCPC, MSc Director, Critical Care Medicine University Health Network & Mount](https://reader038.vdocument.in/reader038/viewer/2022110116/551a845f550346e0158b4b45/html5/thumbnails/2.jpg)
Disclosures
• CareFusion, USA (equipment loan)• Cardinal Health, Canada (equipment service)
![Page 3: HIGH-FREQUENCY OSCILLATION: STATE OF THE EVIDENCE Niall D. Ferguson, MD, FRCPC, MSc Director, Critical Care Medicine University Health Network & Mount](https://reader038.vdocument.in/reader038/viewer/2022110116/551a845f550346e0158b4b45/html5/thumbnails/3.jpg)
![Page 4: HIGH-FREQUENCY OSCILLATION: STATE OF THE EVIDENCE Niall D. Ferguson, MD, FRCPC, MSc Director, Critical Care Medicine University Health Network & Mount](https://reader038.vdocument.in/reader038/viewer/2022110116/551a845f550346e0158b4b45/html5/thumbnails/4.jpg)
![Page 5: HIGH-FREQUENCY OSCILLATION: STATE OF THE EVIDENCE Niall D. Ferguson, MD, FRCPC, MSc Director, Critical Care Medicine University Health Network & Mount](https://reader038.vdocument.in/reader038/viewer/2022110116/551a845f550346e0158b4b45/html5/thumbnails/5.jpg)
Slutsky & Tremblay AJRCCM 1998
![Page 6: HIGH-FREQUENCY OSCILLATION: STATE OF THE EVIDENCE Niall D. Ferguson, MD, FRCPC, MSc Director, Critical Care Medicine University Health Network & Mount](https://reader038.vdocument.in/reader038/viewer/2022110116/551a845f550346e0158b4b45/html5/thumbnails/6.jpg)
ARDS Network
• High Stretch• VT: 11.8
• PPLAT: 32-34
• RR: 18• VMIN: 13
• PEEP: 8
• Mortality 40%
• Low Stretch• VT: 6.2 ml/kg
• PPLAT: 25 cm H2O
• RR: 29• VMIN: 13 L/min
• PEEP: 9 cm H2O
• Mortality 31%**p=0.005
N Engl J Med 2000 342:1301-8
![Page 7: HIGH-FREQUENCY OSCILLATION: STATE OF THE EVIDENCE Niall D. Ferguson, MD, FRCPC, MSc Director, Critical Care Medicine University Health Network & Mount](https://reader038.vdocument.in/reader038/viewer/2022110116/551a845f550346e0158b4b45/html5/thumbnails/7.jpg)
![Page 8: HIGH-FREQUENCY OSCILLATION: STATE OF THE EVIDENCE Niall D. Ferguson, MD, FRCPC, MSc Director, Critical Care Medicine University Health Network & Mount](https://reader038.vdocument.in/reader038/viewer/2022110116/551a845f550346e0158b4b45/html5/thumbnails/8.jpg)
Can We Reduce VILI Further?
![Page 9: HIGH-FREQUENCY OSCILLATION: STATE OF THE EVIDENCE Niall D. Ferguson, MD, FRCPC, MSc Director, Critical Care Medicine University Health Network & Mount](https://reader038.vdocument.in/reader038/viewer/2022110116/551a845f550346e0158b4b45/html5/thumbnails/9.jpg)
HFO vs. Injurious CV in Animals
![Page 10: HIGH-FREQUENCY OSCILLATION: STATE OF THE EVIDENCE Niall D. Ferguson, MD, FRCPC, MSc Director, Critical Care Medicine University Health Network & Mount](https://reader038.vdocument.in/reader038/viewer/2022110116/551a845f550346e0158b4b45/html5/thumbnails/10.jpg)
HFO vs. ‘protective’ CV in animals
![Page 11: HIGH-FREQUENCY OSCILLATION: STATE OF THE EVIDENCE Niall D. Ferguson, MD, FRCPC, MSc Director, Critical Care Medicine University Health Network & Mount](https://reader038.vdocument.in/reader038/viewer/2022110116/551a845f550346e0158b4b45/html5/thumbnails/11.jpg)
Outcomes
30 Day Mortality
HFOV: 37%CMV: 52%
Absolute Risk Reduction: 15%Relative Risk Reduction: 29%
p=0.102
p=0.057 30 d
p=0.078 90 d
HFOV in adults with ARDS appears safe and may improve outcome – more study is needed
![Page 12: HIGH-FREQUENCY OSCILLATION: STATE OF THE EVIDENCE Niall D. Ferguson, MD, FRCPC, MSc Director, Critical Care Medicine University Health Network & Mount](https://reader038.vdocument.in/reader038/viewer/2022110116/551a845f550346e0158b4b45/html5/thumbnails/12.jpg)
![Page 13: HIGH-FREQUENCY OSCILLATION: STATE OF THE EVIDENCE Niall D. Ferguson, MD, FRCPC, MSc Director, Critical Care Medicine University Health Network & Mount](https://reader038.vdocument.in/reader038/viewer/2022110116/551a845f550346e0158b4b45/html5/thumbnails/13.jpg)
HFO
![Page 14: HIGH-FREQUENCY OSCILLATION: STATE OF THE EVIDENCE Niall D. Ferguson, MD, FRCPC, MSc Director, Critical Care Medicine University Health Network & Mount](https://reader038.vdocument.in/reader038/viewer/2022110116/551a845f550346e0158b4b45/html5/thumbnails/14.jpg)
OSCILLATE TRIALNiall D. Ferguson, MD, FRCPC, MSc
Maureen O. Meade, MD, FRCPC, MSc
For the OSCILLATE Investigators and
The Canadian Critical Care Trials Group
![Page 15: HIGH-FREQUENCY OSCILLATION: STATE OF THE EVIDENCE Niall D. Ferguson, MD, FRCPC, MSc Director, Critical Care Medicine University Health Network & Mount](https://reader038.vdocument.in/reader038/viewer/2022110116/551a845f550346e0158b4b45/html5/thumbnails/15.jpg)
![Page 16: HIGH-FREQUENCY OSCILLATION: STATE OF THE EVIDENCE Niall D. Ferguson, MD, FRCPC, MSc Director, Critical Care Medicine University Health Network & Mount](https://reader038.vdocument.in/reader038/viewer/2022110116/551a845f550346e0158b4b45/html5/thumbnails/16.jpg)
![Page 17: HIGH-FREQUENCY OSCILLATION: STATE OF THE EVIDENCE Niall D. Ferguson, MD, FRCPC, MSc Director, Critical Care Medicine University Health Network & Mount](https://reader038.vdocument.in/reader038/viewer/2022110116/551a845f550346e0158b4b45/html5/thumbnails/17.jpg)
Research Question
• For critically ill adults with ARDS, does the early application of high frequency oscillation reduce hospital mortality compared to a high-PEEP, low tidal volume ventilation strategy that incorporates HFO exclusively as ‘rescue’ therapy?
![Page 18: HIGH-FREQUENCY OSCILLATION: STATE OF THE EVIDENCE Niall D. Ferguson, MD, FRCPC, MSc Director, Critical Care Medicine University Health Network & Mount](https://reader038.vdocument.in/reader038/viewer/2022110116/551a845f550346e0158b4b45/html5/thumbnails/18.jpg)
Study Design• International, multicentre randomized clinical trial• Pilot randomized trial
• 2007-2008• N = 94• Acceptability, feasibility
• Current randomized trial• 2009-2012• analysis includes 94 pilot study patients
![Page 19: HIGH-FREQUENCY OSCILLATION: STATE OF THE EVIDENCE Niall D. Ferguson, MD, FRCPC, MSc Director, Critical Care Medicine University Health Network & Mount](https://reader038.vdocument.in/reader038/viewer/2022110116/551a845f550346e0158b4b45/html5/thumbnails/19.jpg)
Population
Target: 1200 adults with moderate-severe ARDS
• Acute respiratory failure• PaO2/FiO2 < 200
• Bilateral airspace disease on CXR• Not attributed primarily to circulatory overload
• Standardized ventilator settings• Vt 6 mL/kg PBW• PEEP > 10 cm H2O
• FiO2 > 0.60
![Page 20: HIGH-FREQUENCY OSCILLATION: STATE OF THE EVIDENCE Niall D. Ferguson, MD, FRCPC, MSc Director, Critical Care Medicine University Health Network & Mount](https://reader038.vdocument.in/reader038/viewer/2022110116/551a845f550346e0158b4b45/html5/thumbnails/20.jpg)
Control GroupHigh PEEP, Low VT Ventilation• Based on the Lung Open Ventilation Study (JAMA ’08)
• Recruitment manoeuvre: 40 cm H2O x 40 seconds
• Initial settings• FiO2 1.0• PEEP 20 cm H2O• Pressure control mode• VT 6 ml/kg PBW • PPLAT ≤ 35 cm H2O
![Page 21: HIGH-FREQUENCY OSCILLATION: STATE OF THE EVIDENCE Niall D. Ferguson, MD, FRCPC, MSc Director, Critical Care Medicine University Health Network & Mount](https://reader038.vdocument.in/reader038/viewer/2022110116/551a845f550346e0158b4b45/html5/thumbnails/21.jpg)
![Page 22: HIGH-FREQUENCY OSCILLATION: STATE OF THE EVIDENCE Niall D. Ferguson, MD, FRCPC, MSc Director, Critical Care Medicine University Health Network & Mount](https://reader038.vdocument.in/reader038/viewer/2022110116/551a845f550346e0158b4b45/html5/thumbnails/22.jpg)
Volume-Pressure Curve
HFOVolume
Pressure
Lower Inflection
Point
Upper Infection
Point
![Page 23: HIGH-FREQUENCY OSCILLATION: STATE OF THE EVIDENCE Niall D. Ferguson, MD, FRCPC, MSc Director, Critical Care Medicine University Health Network & Mount](https://reader038.vdocument.in/reader038/viewer/2022110116/551a845f550346e0158b4b45/html5/thumbnails/23.jpg)
High Frequency Oscillatory Ventilation
• Recruitment manoeuvre: 40 cm H2O x 40 seconds • Initial settings
• FiO2 1.0• mPAW 30 cm H2O• Bias flow 40 L/min• P = 90 cm H2O• f determined by baseline pH…
pH 7.10 = 3.5 HzpH 7.10-7.19 = 4 HzpH 7.20-7.35 = 5 HzpH >7.35 = 6 Hz
![Page 24: HIGH-FREQUENCY OSCILLATION: STATE OF THE EVIDENCE Niall D. Ferguson, MD, FRCPC, MSc Director, Critical Care Medicine University Health Network & Mount](https://reader038.vdocument.in/reader038/viewer/2022110116/551a845f550346e0158b4b45/html5/thumbnails/24.jpg)
Oxygenation Protocols
ControlFiO2 0.3 0.4 0.4 0.4 0.4 0.4 0.5 0.5 0.6 0.7 0.8 0.8 0.9 1.0PEEP 5-10 10 12 14 16 18 18 20 20 20 20 22 22 22-24
HFOFiO2 0.4 0.4 0.4 0.4 0.5 0.6 0.6 0.6 0.7 0.8 0.9 1.0 1.0mPAW 20-24 26 28 30 30 30 32 34 34 34 34 34 36-38
88% < SpO2 < 93% 55 mm Hg < PaO2 < 80 mmHg
![Page 25: HIGH-FREQUENCY OSCILLATION: STATE OF THE EVIDENCE Niall D. Ferguson, MD, FRCPC, MSc Director, Critical Care Medicine University Health Network & Mount](https://reader038.vdocument.in/reader038/viewer/2022110116/551a845f550346e0158b4b45/html5/thumbnails/25.jpg)
Patient Safety
• Volume status assessment prior to initiation• Rx hypotension
• with an increase in PEEP/mPAW
• with stable PEEP/mPAW
• Rx lung over-distention• option to reduce PEEP/mPAW
• option to omit recruitment maneuvers
• Contraindications to recruitment maneuvers• Criteria for instituting ‘rescue’ therapy• 24-hour help line
![Page 26: HIGH-FREQUENCY OSCILLATION: STATE OF THE EVIDENCE Niall D. Ferguson, MD, FRCPC, MSc Director, Critical Care Medicine University Health Network & Mount](https://reader038.vdocument.in/reader038/viewer/2022110116/551a845f550346e0158b4b45/html5/thumbnails/26.jpg)
Interim Analyses
PILOT STUDY ANALYSIS• N = 94
• No stopping rules
CONVENTIONAL INTERIM ANALYSIS • N = 800
• O’Brien-Fleming method; 2-sided test, p = 0.01
SAFETY REVIEWS• N = 300, 500, 700• physiologic changes with study initiation• vasopressors, NMBAs, barotrauma• detailed criteria for requesting mortality data
• 1-sided O’Brien-Fleming method; p = 0.00001, 0.0001, 0.0064
![Page 27: HIGH-FREQUENCY OSCILLATION: STATE OF THE EVIDENCE Niall D. Ferguson, MD, FRCPC, MSc Director, Critical Care Medicine University Health Network & Mount](https://reader038.vdocument.in/reader038/viewer/2022110116/551a845f550346e0158b4b45/html5/thumbnails/27.jpg)
Patients• July 2007 through August 2012 (1 year hiatus)• Began in 12 pilot centers - expanded to total 39 centers
• Canada; United States; Saudi Arabia; Chile; India• (Mexico; UK; Australia; France)
• The Steering Committee terminated the trial on recommendation from the DMC on August 29, 2012• Following the 500-patient safety analysis• 548 of planned 1200 patients randomized
![Page 28: HIGH-FREQUENCY OSCILLATION: STATE OF THE EVIDENCE Niall D. Ferguson, MD, FRCPC, MSc Director, Critical Care Medicine University Health Network & Mount](https://reader038.vdocument.in/reader038/viewer/2022110116/551a845f550346e0158b4b45/html5/thumbnails/28.jpg)
![Page 29: HIGH-FREQUENCY OSCILLATION: STATE OF THE EVIDENCE Niall D. Ferguson, MD, FRCPC, MSc Director, Critical Care Medicine University Health Network & Mount](https://reader038.vdocument.in/reader038/viewer/2022110116/551a845f550346e0158b4b45/html5/thumbnails/29.jpg)
![Page 30: HIGH-FREQUENCY OSCILLATION: STATE OF THE EVIDENCE Niall D. Ferguson, MD, FRCPC, MSc Director, Critical Care Medicine University Health Network & Mount](https://reader038.vdocument.in/reader038/viewer/2022110116/551a845f550346e0158b4b45/html5/thumbnails/30.jpg)
Baseline Characteristics
![Page 31: HIGH-FREQUENCY OSCILLATION: STATE OF THE EVIDENCE Niall D. Ferguson, MD, FRCPC, MSc Director, Critical Care Medicine University Health Network & Mount](https://reader038.vdocument.in/reader038/viewer/2022110116/551a845f550346e0158b4b45/html5/thumbnails/31.jpg)
Baseline Characteristics
![Page 32: HIGH-FREQUENCY OSCILLATION: STATE OF THE EVIDENCE Niall D. Ferguson, MD, FRCPC, MSc Director, Critical Care Medicine University Health Network & Mount](https://reader038.vdocument.in/reader038/viewer/2022110116/551a845f550346e0158b4b45/html5/thumbnails/32.jpg)
Transition on to Protocol
![Page 33: HIGH-FREQUENCY OSCILLATION: STATE OF THE EVIDENCE Niall D. Ferguson, MD, FRCPC, MSc Director, Critical Care Medicine University Health Network & Mount](https://reader038.vdocument.in/reader038/viewer/2022110116/551a845f550346e0158b4b45/html5/thumbnails/33.jpg)
Ventilation Parameters Day 1
HFOV Control
Delta P 87 (7.8)
Frequency 5.5 (1)
mPaw 31 (2.6) 24 (4)
VT 6.1 (1.3)
PEEP 18 (3.2)
PPLAT 32 (5.7)
FIO2 0.62 (0.19) 0.64 (0.20)
PaO2 84 (38) 94 (52)
PaCO2 46 (15) 52 (17)
Fluid Balance
2897 (3124)
2410 (2901)
Day 1 Day 3 Day 7
HFOV Control HFOV Control HFOV Control
Delta P 87 (7.8) 85 (9.5) 87 (7.3)
Frequency 5.5 (1) 6.8 (2) 6.8 (2)
mPaw 31 (2.6) 24 (4) 26 (6.8) 20 (6.4) 21 (8.9) 18 (7.1)
VT 6.1 (1.3) 6.6 (1.8) 7.0 (1.8)
PEEP 18 (3.2) 13 (4.5) 12 (4.6)
PPLAT 32 (5.7) 27 (8.1) 24 (8.7)
FIO2 0.62 (0.19) 0.64 (0.20) 0.50 (0.16) 0.45 (0.14) 0.45 (0.16) 0.42 (0.16)
PaO2 84 (38) 94 (52) 78 (21) 73 (18) 76 (26) 75 (23)
PaCO2 46 (15) 52 (17) 51 (15) 46 (11) 50 (17) 47 (15)
Fluid Balance
2897 (3124)
2410 (2901)
1519 (2430)
1147 (2486)
-87 (2072)
-215 (2298)
Day 1 Day 3
HFOV Control HFOV Control
Delta P 87 (7.8) 85 (9.5)
Frequency 5.5 (1) 6.8 (2)
mPaw 31 (2.6) 24 (4) 26 (6.8) 20 (6.4)
VT 6.1 (1.3) 6.6 (1.8)
PEEP 18 (3.2) 13 (4.5)
PPLAT 32 (5.7) 27 (8.1)
FIO2 0.62 (0.19) 0.64 (0.20) 0.50 (0.16) 0.45 (0.14)
PaO2 84 (38) 94 (52) 78 (21) 73 (18)
PaCO2 46 (15) 52 (17) 51 (15) 46 (11)
Fluid Balance
2897 (3124)
2410 (2901)
1519 (2430)
1147 (2486)
![Page 34: HIGH-FREQUENCY OSCILLATION: STATE OF THE EVIDENCE Niall D. Ferguson, MD, FRCPC, MSc Director, Critical Care Medicine University Health Network & Mount](https://reader038.vdocument.in/reader038/viewer/2022110116/551a845f550346e0158b4b45/html5/thumbnails/34.jpg)
Ventilation Groups• HFO Group
• 270/275 (98%) patients received HFO• Median 3 (2-8) days of HFO• 222 (81%) moved to conventional ventilation
• Median 5 (2-7) days of conventional
• Control Group• All patients received conventional ventilation • 34 (12.5%) converted to HFO after 2 (1-4) days
• Median 7 (5-15) days of HFO
![Page 35: HIGH-FREQUENCY OSCILLATION: STATE OF THE EVIDENCE Niall D. Ferguson, MD, FRCPC, MSc Director, Critical Care Medicine University Health Network & Mount](https://reader038.vdocument.in/reader038/viewer/2022110116/551a845f550346e0158b4b45/html5/thumbnails/35.jpg)
Main Results
![Page 36: HIGH-FREQUENCY OSCILLATION: STATE OF THE EVIDENCE Niall D. Ferguson, MD, FRCPC, MSc Director, Critical Care Medicine University Health Network & Mount](https://reader038.vdocument.in/reader038/viewer/2022110116/551a845f550346e0158b4b45/html5/thumbnails/36.jpg)
Survival Curve
![Page 37: HIGH-FREQUENCY OSCILLATION: STATE OF THE EVIDENCE Niall D. Ferguson, MD, FRCPC, MSc Director, Critical Care Medicine University Health Network & Mount](https://reader038.vdocument.in/reader038/viewer/2022110116/551a845f550346e0158b4b45/html5/thumbnails/37.jpg)
All Subgroups
![Page 38: HIGH-FREQUENCY OSCILLATION: STATE OF THE EVIDENCE Niall D. Ferguson, MD, FRCPC, MSc Director, Critical Care Medicine University Health Network & Mount](https://reader038.vdocument.in/reader038/viewer/2022110116/551a845f550346e0158b4b45/html5/thumbnails/38.jpg)
Cointerventions
![Page 39: HIGH-FREQUENCY OSCILLATION: STATE OF THE EVIDENCE Niall D. Ferguson, MD, FRCPC, MSc Director, Critical Care Medicine University Health Network & Mount](https://reader038.vdocument.in/reader038/viewer/2022110116/551a845f550346e0158b4b45/html5/thumbnails/39.jpg)
Midazolam doses in week 1
HFOV 199 (100-382) vs. Control 141 (68-240) mg/day; P<0.001
![Page 40: HIGH-FREQUENCY OSCILLATION: STATE OF THE EVIDENCE Niall D. Ferguson, MD, FRCPC, MSc Director, Critical Care Medicine University Health Network & Mount](https://reader038.vdocument.in/reader038/viewer/2022110116/551a845f550346e0158b4b45/html5/thumbnails/40.jpg)
Opioid doses in week 1
HFOV 2980 (1258-4800) vs. Control 2400 (1140-4430) μg/day; P=0.06
![Page 41: HIGH-FREQUENCY OSCILLATION: STATE OF THE EVIDENCE Niall D. Ferguson, MD, FRCPC, MSc Director, Critical Care Medicine University Health Network & Mount](https://reader038.vdocument.in/reader038/viewer/2022110116/551a845f550346e0158b4b45/html5/thumbnails/41.jpg)
Discussion• Early application of HFOV associated with harm compared
with a high PEEP, low VT strategy allowing HFOV only for severe refractory hypoxemia• HFOV patients received higher mPaw, more sedatives, more
NMBAs, more vasoactive drugs• Subgroup analysis suggest that this finding is robust across severity
and experience of groups
• Studies that stop early often overestimate effects• No benefit of HFOV
• Possibly because we used a more effective control strategy
• Harm with HFOV?• Chance• Higher mPaw leading to hemodynamic compromise• Hemodynamic effects of increased sedatives• Possible increased barotrauma and VILI
![Page 42: HIGH-FREQUENCY OSCILLATION: STATE OF THE EVIDENCE Niall D. Ferguson, MD, FRCPC, MSc Director, Critical Care Medicine University Health Network & Mount](https://reader038.vdocument.in/reader038/viewer/2022110116/551a845f550346e0158b4b45/html5/thumbnails/42.jpg)
Discussion• HFOV strategy chosen based on preclinical data and pilot
physiological data• Resulted in relatively high mPaw• Other HFOV strategies using lower mPaw may have different
effects
• Implications for care• Results raise serious concerns about use of early HFOV for adults
with moderate-severe ARDS• Even for those with refractory hypoxemia, results increase
uncertainty about possible benefits of HFOV
![Page 43: HIGH-FREQUENCY OSCILLATION: STATE OF THE EVIDENCE Niall D. Ferguson, MD, FRCPC, MSc Director, Critical Care Medicine University Health Network & Mount](https://reader038.vdocument.in/reader038/viewer/2022110116/551a845f550346e0158b4b45/html5/thumbnails/43.jpg)
Conclusions• HFOV as used in the OSCILLATE trial does not improve
survival and is likely harmful compared with a high PEEP, low tidal volume conventional strategy allowing HFOV only as rescue therapy
![Page 44: HIGH-FREQUENCY OSCILLATION: STATE OF THE EVIDENCE Niall D. Ferguson, MD, FRCPC, MSc Director, Critical Care Medicine University Health Network & Mount](https://reader038.vdocument.in/reader038/viewer/2022110116/551a845f550346e0158b4b45/html5/thumbnails/44.jpg)
![Page 45: HIGH-FREQUENCY OSCILLATION: STATE OF THE EVIDENCE Niall D. Ferguson, MD, FRCPC, MSc Director, Critical Care Medicine University Health Network & Mount](https://reader038.vdocument.in/reader038/viewer/2022110116/551a845f550346e0158b4b45/html5/thumbnails/45.jpg)
![Page 46: HIGH-FREQUENCY OSCILLATION: STATE OF THE EVIDENCE Niall D. Ferguson, MD, FRCPC, MSc Director, Critical Care Medicine University Health Network & Mount](https://reader038.vdocument.in/reader038/viewer/2022110116/551a845f550346e0158b4b45/html5/thumbnails/46.jpg)
30-Day Mortality:HFO 41.7% vs. 41.1%
Hospital Mortality:HFO 50.1% vs. 48.4%
![Page 47: HIGH-FREQUENCY OSCILLATION: STATE OF THE EVIDENCE Niall D. Ferguson, MD, FRCPC, MSc Director, Critical Care Medicine University Health Network & Mount](https://reader038.vdocument.in/reader038/viewer/2022110116/551a845f550346e0158b4b45/html5/thumbnails/47.jpg)
![Page 48: HIGH-FREQUENCY OSCILLATION: STATE OF THE EVIDENCE Niall D. Ferguson, MD, FRCPC, MSc Director, Critical Care Medicine University Health Network & Mount](https://reader038.vdocument.in/reader038/viewer/2022110116/551a845f550346e0158b4b45/html5/thumbnails/48.jpg)